Factory Mutual Insurance Co. decreased its position in shares of Eli Lilly and Co (NYSE:LLY) by 41.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 254,300 shares of the company’s stock after selling 177,000 shares during the period. Factory Mutual Insurance Co.’s holdings in Eli Lilly and were worth $21,389,000 as of its most recent filing with the SEC.
Other hedge funds have also made changes to their positions in the company. Tarbox Group Inc. raised its stake in shares of Eli Lilly and by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock worth $124,000 after buying an additional 11 shares during the period. First Citizens Bank & Trust Co. raised its stake in shares of Eli Lilly and by 0.3% in the third quarter. First Citizens Bank & Trust Co. now owns 5,920 shares of the company’s stock worth $476,000 after buying an additional 18 shares during the period. Enterprise Financial Services Corp raised its stake in shares of Eli Lilly and by 0.9% in the third quarter. Enterprise Financial Services Corp now owns 2,150 shares of the company’s stock worth $173,000 after buying an additional 20 shares during the period. Jackson Grant Investment Advisers Inc. raised its stake in shares of Eli Lilly and by 0.7% in the third quarter. Jackson Grant Investment Advisers Inc. now owns 3,931 shares of the company’s stock worth $316,000 after buying an additional 26 shares during the period. Finally, Accredited Investors Inc. raised its stake in shares of Eli Lilly and by 1.0% in the third quarter. Accredited Investors Inc. now owns 3,257 shares of the company’s stock worth $261,000 after buying an additional 32 shares during the period. Institutional investors and hedge funds own 75.15% of the company’s stock.
Shares of Eli Lilly and Co (NYSE:LLY) traded down 0.64% during midday trading on Friday, hitting $77.80. The stock had a trading volume of 5,091,841 shares. The stock’s 50 day moving average price is $82.24 and its 200 day moving average price is $78.19. The firm has a market cap of $82.18 billion, a price-to-earnings ratio of 37.62 and a beta of 0.30. Eli Lilly and Co has a 12 month low of $64.18 and a 12 month high of $86.72.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 25th. The company reported $0.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.96 by $0.02. Eli Lilly and had a return on equity of 24.74% and a net margin of 12.90%. The firm had revenue of $5.23 billion for the quarter, compared to analysts’ expectations of $5.22 billion. During the same period in the previous year, the firm earned $0.83 EPS. The business’s quarterly revenue was up 7.5% on a year-over-year basis. On average, equities analysts forecast that Eli Lilly and Co will post $4.12 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 9th. Stockholders of record on Monday, May 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, May 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.66%. Eli Lilly and’s payout ratio is currently 80.62%.
TRADEMARK VIOLATION WARNING: This article was first reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.themarketsdaily.com/2017/05/20/eli-lilly-and-co-lly-stake-cut-by-factory-mutual-insurance-co-updated.html.
A number of brokerages have commented on LLY. Cowen and Company boosted their price target on shares of Eli Lilly and from $85.00 to $95.00 and gave the company an “outperform” rating in a research note on Monday, April 17th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a report on Tuesday, April 4th. Citigroup Inc reaffirmed a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a report on Thursday, April 6th. Morgan Stanley downgraded shares of Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 price objective on the stock. in a report on Monday, April 17th. Finally, Argus downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the company. Eli Lilly and presently has an average rating of “Buy” and a consensus target price of $87.56.
In other news, SVP Enrique A. Conterno sold 25,000 shares of Eli Lilly and stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $82.76, for a total transaction of $2,069,000.00. Following the transaction, the senior vice president now directly owns 114,217 shares of the company’s stock, valued at approximately $9,452,598.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $84.67, for a total value of $17,780,700.00. Following the sale, the insider now directly owns 124,690,804 shares in the company, valued at approximately $10,557,570,374.68. The disclosure for this sale can be found here. 0.20% of the stock is owned by insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with MarketBeat.com's FREE daily email newsletter.